1
|
Sadakata M, Fujii K, Kaneko R, Hosoya E, Sugimoto H, Kawabata-Iwakawa R, Kasamatsu T, Hongo S, Koshidaka Y, Takase A, Iijima T, Takao K, Sadakata T. Maternal immunoglobulin G affects brain development of mouse offspring. J Neuroinflammation 2024; 21:114. [PMID: 38698428 PMCID: PMC11064405 DOI: 10.1186/s12974-024-03100-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Accepted: 04/14/2024] [Indexed: 05/05/2024] Open
Abstract
Maternal immunoglobulin (Ig)G is present in breast milk and has been shown to contribute to the development of the immune system in infants. In contrast, maternal IgG has no known effect on early childhood brain development. We found maternal IgG immunoreactivity in microglia, which are resident macrophages of the central nervous system of the pup brain, peaking at postnatal one week. Strong IgG immunoreactivity was observed in microglia in the corpus callosum and cerebellar white matter. IgG stimulation of primary cultured microglia activated the type I interferon feedback loop by Syk. Analysis of neonatal Fc receptor knockout (FcRn KO) mice that could not take up IgG from their mothers revealed abnormalities in the proliferation and/or survival of microglia, oligodendrocytes, and some types of interneurons. Moreover, FcRn KO mice also exhibited abnormalities in social behavior and lower locomotor activity in their home cages. Thus, changes in the mother-derived IgG levels affect brain development in offsprings.
Collapse
Affiliation(s)
- Mizuki Sadakata
- Education and Research Support Center, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan.
| | - Kazuki Fujii
- Department of Behavioral Physiology, Faculty of Medicine, University of Toyama, Toyama, 930-0194, Japan
- Research Center for Idling Brain Science, University of Toyama, Toyama, 930-0194, Japan
- Life Science Research Center, University of Toyama, Toyama, 930-0194, Japan
| | - Ryosuke Kaneko
- Medical Genetics Research Center, Nara Medical University, Kashihara, Nara, 634-8521, Japan
| | - Emi Hosoya
- Education and Research Support Center, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan
| | - Hisako Sugimoto
- Education and Research Support Center, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan
| | - Reika Kawabata-Iwakawa
- Division of Integrated Oncology Research, Gunma University Initiative for Advanced Research (GIAR), Gunma University, Maebashi, Gunma, 371-8511, Japan
| | - Tetsuhiro Kasamatsu
- Department of Medical Technology and Clinical Engineering, Gunma University of Health and Walfare, Maebashi, Gunma, 371-0823, Japan
| | - Shoko Hongo
- Life Science Research Center, University of Toyama, Toyama, 930-0194, Japan
| | - Yumie Koshidaka
- Life Science Research Center, University of Toyama, Toyama, 930-0194, Japan
| | - Akinori Takase
- Medical Science College Office, Tokai University, Isehara, Kanagawa, 259-1193, Japan
| | - Takatoshi Iijima
- Department of Molecular Life Science, Division of Basic Medical Science and Molecular Medicine, School of Medicine, Tokai University, Isehara, Kanagawa, 259-1193, Japan
| | - Keizo Takao
- Department of Behavioral Physiology, Faculty of Medicine, University of Toyama, Toyama, 930-0194, Japan
- Research Center for Idling Brain Science, University of Toyama, Toyama, 930-0194, Japan
- Life Science Research Center, University of Toyama, Toyama, 930-0194, Japan
| | - Tetsushi Sadakata
- Education and Research Support Center, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan.
| |
Collapse
|
2
|
Kasamatsu T. Implications of Senescent T Cells for Cancer Immunotherapy. Cancers (Basel) 2023; 15:5835. [PMID: 38136380 PMCID: PMC10742305 DOI: 10.3390/cancers15245835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 12/11/2023] [Accepted: 12/13/2023] [Indexed: 12/24/2023] Open
Abstract
T-cell senescence is thought to result from the age-related loss of the ability to mount effective responses to pathogens and tumor cells. In addition to aging, T-cell senescence is caused by repeated antigenic stimulation and chronic inflammation. Moreover, we demonstrated that T-cell senescence was induced by treatment with DNA-damaging chemotherapeutic agents. The characteristics of therapy-induced senescent T (TIS-T) cells and general senescent T cells are largely similar. Senescent T cells demonstrate an increase in the senescence-associated beta-galactosidase-positive population, cell cycle arrest, secretion of senescence-associated secretory phenotypic factors, and metabolic reprogramming. Furthermore, senescent T cells downregulate the expression of the co-stimulatory molecules CD27 and CD28 and upregulate natural killer cell-related molecules. Moreover, TIS-T cells showed increased PD-1 expression. However, the loss of proliferative capacity and decreased expression of co-stimulatory molecules associated with T-cell senescence cause a decrease in T-cell immunocompetence. In this review, we discuss the characteristics of senescent T-cells, including therapy-induced senescent T cells.
Collapse
Affiliation(s)
- Tetsuhiro Kasamatsu
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-machi, Maebashi 371-8514, Gunma, Japan
| |
Collapse
|
3
|
Kasamatsu T, Awata-Shiraiwa M, Ishihara R, Murakami Y, Masuda Y, Gotoh N, Oda T, Yokohama A, Matsumura I, Handa H, Tsukamoto N, Murakami H, Saitoh T. Sub-lethal doses of chemotherapeutic agents induce senescence in T cells and upregulation of PD-1 expression. Clin Exp Med 2023; 23:2695-2703. [PMID: 36913034 DOI: 10.1007/s10238-023-01034-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 02/28/2023] [Indexed: 03/14/2023]
Abstract
Cellular senescence is a stable cell cycle arrest, usually in response to internal and/or external stress, including telomere dysfunction, abnormal cellular growth, and DNA damage. Several chemotherapeutic drugs, such as melphalan (MEL) and doxorubicin (DXR), induce cellular senescence in cancer cells. However, it is not clear whether these drugs induce senescence in immune cells. We evaluated the induction of cellular senescence in T cells were derived from human peripheral blood mononuclear cells (PBMNCs) in healthy donors using sub-lethal doses of chemotherapeutic agents. The PBMNCs were kept overnight in RPMI 1640 medium with 2% phytohemagglutinin and 10% fetal bovine serum and then cultured in RPMI 1640 with 20 ng/mL IL-2 and sub-lethal doses of chemotherapeutic drugs (2 μM MEL and 50 nM DXR) for 48 h. Sub-lethal doses of chemotherapeutic agents induced phenotypes associated with senescence, such as the formation of γH2AX nuclear foci, cell proliferation arrest, and induction of senescence-associated beta-galactosidase (SA-β-Gal) activity, (control vs. MEL, DXR; median mean fluorescence intensity (MFI) 1883 (1130-2163) vs. 2233 (1385-2254), 2406.5 (1377-3119), respectively) in T cells. IL6 and SPP1 mRNA, which are senescence-associated secretory phenotype (SASP) factors, were significantly upregulated by sublethal doses of MEL and DXR compared to the control (P = 0.043 and 0.018, respectively). Moreover, sub-lethal doses of chemotherapeutic agents significantly enhanced the expression of programmed death 1 (PD-1) on CD3 + CD4 + and CD3 + CD8 + T cells compared to the control (CD4 + T cells; P = 0.043, 0.043, and 0.043, respectively, CD8 + T cells; P = 0.043, 0.043, and 0.043, respectively). Our results suggest that sub-lethal doses of chemotherapeutic agents induce senescence in T cells and tumor immunosuppression by upregulating PD-1 expression on T cells.
Collapse
Affiliation(s)
- Tetsuhiro Kasamatsu
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-8514, Japan.
| | - Maaya Awata-Shiraiwa
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-8514, Japan
- Gunma University of Health and Welfare, 191-1 Kawamagari-Cho, Maebashi, Gunma, 371-0823, Japan
| | - Rei Ishihara
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-8514, Japan
- Gunma University of Health and Welfare, 191-1 Kawamagari-Cho, Maebashi, Gunma, 371-0823, Japan
| | - Yuki Murakami
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-8514, Japan
- Gunma University of Health and Welfare, 191-1 Kawamagari-Cho, Maebashi, Gunma, 371-0823, Japan
| | - Yuta Masuda
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-8514, Japan
- Gunma University of Health and Welfare, 191-1 Kawamagari-Cho, Maebashi, Gunma, 371-0823, Japan
| | - Nanami Gotoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-8514, Japan
| | - Tsukasa Oda
- Institute of Molecular and Cellular Regulation, Gunma University, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-8511, Japan
| | - Akihiko Yokohama
- Blood Transfusion Service, Gunma University Hospital, 3-39-15 Showa-Machi, Maebashi, Gunma, 371-8511, Japan
| | - Ikuko Matsumura
- Department of Hematology, Gunma University, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-0034, Japan
| | - Hiroshi Handa
- Department of Hematology, Gunma University, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-0034, Japan
| | - Norifumi Tsukamoto
- Oncology Center, Gunma University Hospital, 3-39-15 Showa-Machi, Maebashi, Gunma, 371-8511, Japan
| | - Hirokazu Murakami
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-8514, Japan
- Gunma University of Health and Welfare, 191-1 Kawamagari-Cho, Maebashi, Gunma, 371-0823, Japan
| | - Takayuki Saitoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-8514, Japan
| |
Collapse
|
4
|
Awata-Shiraiwa M, Yokohama A, Kanai Y, Gotoh N, Kasamatsu T, Handa H, Saitoh T, Murakami H, Hirato J, Ikota H, Tsukamoto N. Waldenström Macroglobulinemia and Non-IgM-Type Lymphoplasmacytic Lymphoma Are Genetically Similar. Acta Haematol 2023; 146:384-390. [PMID: 36917966 DOI: 10.1159/000530100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Accepted: 02/24/2023] [Indexed: 03/16/2023]
Abstract
INTRODUCTION Waldenström macroglobulinemia (WM) represents a subset of lymphoplasmacytic lymphoma (LPL) with the immunoglobulin (Ig)M paraprotein. MYD88 L265P and CXCR4 mutations are common mutations in WM patients, and mutations in ARID1A and KMT2D (MLL2) have also been reported. However, little information has been accumulated on genetic changes in LPL with other paraproteins like IgG. METHODS We therefore aimed to evaluate genetic differences between WM and LPL with non-IgM paraprotein (non-IgM-type LPL) using targeted next-generation sequencing (NGS) in 20 Japanese patients (10 with WM, 10 with non-IgM-type LPL). RESULTS Mutations were detected in ARID1A (10%), CXCR4 (20%), MYD88 (90%), and KMT2D (0%) for WM patients and in ARID1A (10%), CXCR4 (20%), MYD88 (70%), and KMT2D (10%) for non-IgM-type LPL patients. No significant differences were identified. No mutations were detected in NOTCH2, PRDM1, CD274 (PD-L1), PDCD1LG2 (PD-L2), RAG2, MYBBP1A, TP53, or CD79B. DISCUSSION Mutant allele frequency in MYD88 L265P did not differ significantly between WM and non-IgM-type LPL. Most mutations detected by NGS were subclonal following MYD88 L265P, although one non-IgM-type LPL patient harbored only CXCR4 S338X mutation. Our NGS analyses reveal genetic characteristics in LPL patients and suggest genetic similarities between these two subsets of LPL, WM and non-IgM-type.
Collapse
Affiliation(s)
- Maaya Awata-Shiraiwa
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
- Gunma University of Health and Welfare, Maebashi, Japan
| | - Akihiko Yokohama
- Blood Transfusion Service, Gunma University Hospital, Maebashi, Japan
| | - Yukihiro Kanai
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | - Nanami Gotoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | - Tetsuhiro Kasamatsu
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | - Hiroshi Handa
- Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Takayuki Saitoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | - Hirokazu Murakami
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
- Gunma University of Health and Welfare, Maebashi, Japan
| | - Junko Hirato
- Clinical Department of Pathology, Public Tomioka General Hospital, Tomioka, Japan
| | - Hayato Ikota
- Clinical Department of Pathology, Gunma University Hospital, Maebashi, Japan
| | | |
Collapse
|
5
|
Oda T, Gotoh N, Kasamatsu T, Handa H, Saitoh T, Sasaki N. DNA damage-induced cellular senescence is regulated by 53BP1 accumulation in the nuclear foci and phase separation. Cell Prolif 2023:e13398. [PMID: 36642815 DOI: 10.1111/cpr.13398] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 12/14/2022] [Accepted: 12/28/2022] [Indexed: 01/17/2023] Open
Abstract
Cellular senescence is linked to a wide range of age-related diseases and can be triggered by a variety of stresses, including DNA damage. A variety of genotoxic stressors, such as anti-cancer drugs, cause DNA double-strand breaks (DSBs), which trigger the accumulation of the tumour suppressor protein p53 in the nucleus. Cellular stresses stabilize and activate the p53 signalling pathway, which regulates various cellular processes, such as apoptosis, DNA repair, and senescence. Although p53 signalling is a well-known tumour suppressor pathway, it remains unclear how it is regulated during cellular senescence. Here, we show that p53-binding protein 1 (53BP1) accumulation in the nuclear foci is required for DNA damage-induced cellular senescence via p53 activation. In human immortalized fibroblast, shRNA-mediated 53BP1 depletion decreased not only the expression of p53-target genes but also the cellular senescence induced by adriamycin treatment. Furthermore, we confirmed that DSBs trigger the hyperaccumulation of 53BP1 in the nuclear foci, which plays a key role in the regulation of cellular senescence. To prevent the accumulation of 53BP1 in the nuclear foci, we used phase separation inhibitors, and siRNA against RNF168, which accumulates at DSB loci and forms complexes with 53BP1. This blocks the formation of 53BP1 nuclear foci and DNA damage-induced cellular senescence by activating the p53 signaling pathway. In conclusion, we demonstrated that increased accumulation of 53BP1 in the nuclear foci following DNA damage activates p53 and governs cellular senescence via a liquid-liquid phase separation mechanism.
Collapse
Affiliation(s)
- Tsukasa Oda
- Laboratory of Mucosal Ecosystem Design, The Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma, Japan
| | - Nanami Gotoh
- Graduate School of Health Sciences, Gunma University, Maebashi, Gunma, Japan
| | - Tetsuhiro Kasamatsu
- Graduate School of Health Sciences, Gunma University, Maebashi, Gunma, Japan
| | - Hiroshi Handa
- Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan
| | - Takayuki Saitoh
- Graduate School of Health Sciences, Gunma University, Maebashi, Gunma, Japan
| | - Nobuo Sasaki
- Laboratory of Mucosal Ecosystem Design, The Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma, Japan
| |
Collapse
|
6
|
Murakami Y, Kimura-Masuda K, Oda T, Matsumura I, Masuda Y, Ishihara R, Watanabe S, Kuroda Y, Kasamatsu T, Gotoh N, Takei H, Kobayashi N, Saitoh T, Murakami H, Handa H. MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression. Genes (Basel) 2022; 14:100. [PMID: 36672841 PMCID: PMC9859619 DOI: 10.3390/genes14010100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 12/23/2022] [Accepted: 12/24/2022] [Indexed: 12/31/2022] Open
Abstract
MicroRNAs (miRNAs and miRs) are small (19-25 base pairs) non-coding RNAs with the ability to modulate gene expression. Previously, we showed that the miR-34 family is downregulated in multiple myeloma (MM) as the cancer progressed. In this study, we aimed to clarify the mechanism of miRNA dysregulation in MM. We focused particularly on the interaction between MYC and the TP53-miR34 axis because there is a discrepancy between increased TP53 and decreased miR-34 expressions in MM. Using the nutlin-3 or Tet-on systems, we caused wild-type (WT) p53 protein accumulation in human MM cell lines (HMCLs) and observed upregulated miR-34 expression. Next, we found that treatment with an Myc inhibitor alone did not affect miR-34 expression levels, but when it was coupled with p53 accumulation, miR-34 expression increased. In contrast, forced MYC activation by the MYC-ER system reduced nutlin-3-induced miR-34 expression. We also observed that TP53 and MYC were negatively correlated with mature miR-34 expressions in the plasma cells of patients with MM. Our results suggest that MYC participates in the suppression of p53-dependent miRNA expressions. Because miRNA expression suppresses tumors, its inhibition leads to MM development and malignant transformation.
Collapse
Affiliation(s)
- Yuki Murakami
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi 371-8510, Japan
| | - Kei Kimura-Masuda
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi 371-8510, Japan
| | - Tsukasa Oda
- Laboratory of Mucosal Ecosystem Design, The Institute for Molecular and Cellular Regulation, Gunma University, Maebashi 371-8510, Japan
| | - Ikuko Matsumura
- Department of Hematology, Gunma University Graduate School of Medicine, Maebashi 371-8510, Japan
| | - Yuta Masuda
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi 371-8510, Japan
- Faculty of Medical Technology and Clinical Engineering, Gunma University of Health and Welfare, Maebashi 371-0823, Japan
| | - Rei Ishihara
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi 371-8510, Japan
| | - Saki Watanabe
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi 371-8510, Japan
| | - Yuko Kuroda
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi 371-8510, Japan
| | - Tetsuhiro Kasamatsu
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi 371-8510, Japan
| | - Nanami Gotoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi 371-8510, Japan
| | - Hisashi Takei
- Department of Hematology, Gunma University Graduate School of Medicine, Maebashi 371-8510, Japan
| | - Nobuhiko Kobayashi
- Department of Hematology, Gunma University Graduate School of Medicine, Maebashi 371-8510, Japan
| | - Takayuki Saitoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi 371-8510, Japan
| | - Hirokazu Murakami
- Faculty of Medical Technology and Clinical Engineering, Gunma University of Health and Welfare, Maebashi 371-0823, Japan
| | - Hiroshi Handa
- Department of Hematology, Gunma University Graduate School of Medicine, Maebashi 371-8510, Japan
| |
Collapse
|
7
|
Oda T, Nakamura R, Kasamatsu T, Gotoh N, Okuda K, Saitoh T, Handa H, Murakami H, Yamashita T. DNA-double strand breaks enhance the expression of major histocompatibility complex class II through the ATM-NF-κΒ-IRF1-CIITA pathway. Cancer Gene Ther 2022; 29:225-240. [PMID: 33619341 DOI: 10.1038/s41417-021-00302-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 01/18/2021] [Accepted: 01/28/2021] [Indexed: 01/31/2023]
Abstract
Major histocompatibility complex class II (MHC II) is important for the adaptive immune response because MHC II presents processed antigens to a cluster of differentiation 4 (CD4)-positive T-cells. Conventional doses of chemotherapeutic agents induce tumor cell death by causing DNA double-strand breaks (DSBs). However, cellular responses caused by sub-lethal doses of chemotherapeutic agents are poorly understood. In this study, using low doses of chemotherapeutic agents, we showed that DSBs enhanced the expression of MHC II on cells that originate from antigen-presenting cells (APCs). These agents induced the MHC class II transactivator (CIITA), the master regulator of MHC II, and interferon regulatory factor 1 (IRF1), a transcription factor for CIITA. Short hairpin RNA against IRF1 suppressed chemotherapeutic agent-induced CIITA expression, whereas exogenous expression of IRF1 induced CIITA. Inhibition of ataxia-telangiectasia mutated (ATM), a DSB-activated kinase, suppressed induction of IRF1, CIITA, and MHC II. Similar results were observed by inhibiting NF-κB, a downstream target of ATM. These results suggest that DSBs induce MHC II activity via the ATM-NF-κB-IRF1-CIITA pathway in cells that intrinsically present antigens. Additionally, chemotherapeutic agents induced T-cell regulatory molecules. Our findings suggest that chemotherapeutic agents enhance the antigen presentation activity of APCs for T-cell activation.
Collapse
Affiliation(s)
- Tsukasa Oda
- Laboratory of Molecular Genetics, The Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma, Japan. .,Center for Food Science and Wellness, Gunma University, Maebashi, Gunma, Japan.
| | - Ruri Nakamura
- Graduate School of Health Sciences, Gunma University, Maebashi, Gunma, Japan
| | - Tetsuhiro Kasamatsu
- Graduate School of Health Sciences, Gunma University, Maebashi, Gunma, Japan
| | - Nanami Gotoh
- Graduate School of Health Sciences, Gunma University, Maebashi, Gunma, Japan
| | - Keiko Okuda
- Department of Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan
| | - Takayuki Saitoh
- Graduate School of Health Sciences, Gunma University, Maebashi, Gunma, Japan
| | - Hiroshi Handa
- Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan
| | - Hirokazu Murakami
- Graduate School of Health Sciences, Gunma University, Maebashi, Gunma, Japan.,Gunma University of Health and Welfare, Maebashi, Gunma, Japan
| | - Takayuki Yamashita
- Laboratory of Molecular Genetics, The Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma, Japan
| |
Collapse
|
8
|
Handa H, Honma K, Oda T, Kobayashi N, Kuroda Y, Kimura-Masuda K, Watanabe S, Ishihara R, Murakami Y, Masuda Y, Tahara KI, Takei H, Kasamatsu T, Saitoh T, Murakami H. Long Noncoding RNA PVT1 Is Regulated by Bromodomain Protein BRD4 in Multiple Myeloma and Is Associated with Disease Progression. Int J Mol Sci 2020; 21:ijms21197121. [PMID: 32992461 PMCID: PMC7583953 DOI: 10.3390/ijms21197121] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Revised: 09/08/2020] [Accepted: 09/24/2020] [Indexed: 12/14/2022] Open
Abstract
Long noncoding RNAs (lncRNAs) are deregulated in human cancers and are associated with disease progression. Plasmacytoma Variant Translocation 1 (PVT1), a lncRNA, is located adjacent to the gene MYC, which has been linked to multiple myeloma (MM). PVT1 is expressed in MM and is associated with carcinogenesis. However, its role and regulation remain uncertain. We examined PVT1/MYC expression using real-time PCR in plasma cells purified from 59 monoclonal gammopathy of undetermined significance (MGUS) and 140 MM patients. The MM cell lines KMS11, KMS12PE, OPM2, and RPMI8226 were treated with JQ1, an MYC super-enhancer inhibitor, or MYC inhibitor 10058-F4. The expression levels of PVT1 and MYC were significantly higher in MM than in MGUS (p < 0.0001) and were positively correlated with disease progression (r = 0.394, p < 0.0001). JQ1 inhibited cell proliferation and decreased the expression levels of MYC and PVT1. However, 10054-F4 did not alter the expression level of PVT1. The positive correlation between MYC and PVT1 in patients, the synchronous downregulation of MYC and PVT1 by JQ1, and the lack of effect of the MYC inhibitor on PVT1 expression suggest that the expression of these two genes is co-regulated by a super-enhancer. Cooperative effects between these two genes may contribute to MM pathogenesis and progression.
Collapse
Affiliation(s)
- Hiroshi Handa
- Department of Hematology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (N.K.); (K.-i.T.); (H.T.)
- Correspondence: ; Tel.: +81-27-220-8166; Fax: +81-27-220-8173
| | - Kazuki Honma
- Department of Laboratory Science, Gunma University Graduate School of Health Science, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (K.H.); (Y.K.); (K.K.-M.); (S.W.); (R.I.); (Y.M.); (Y.M.); (T.K.); (T.S.); (H.M.)
| | - Tsukasa Oda
- Institute of Molecular and Cellular Regulation, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan;
| | - Nobuhiko Kobayashi
- Department of Hematology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (N.K.); (K.-i.T.); (H.T.)
| | - Yuko Kuroda
- Department of Laboratory Science, Gunma University Graduate School of Health Science, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (K.H.); (Y.K.); (K.K.-M.); (S.W.); (R.I.); (Y.M.); (Y.M.); (T.K.); (T.S.); (H.M.)
| | - Kei Kimura-Masuda
- Department of Laboratory Science, Gunma University Graduate School of Health Science, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (K.H.); (Y.K.); (K.K.-M.); (S.W.); (R.I.); (Y.M.); (Y.M.); (T.K.); (T.S.); (H.M.)
| | - Saki Watanabe
- Department of Laboratory Science, Gunma University Graduate School of Health Science, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (K.H.); (Y.K.); (K.K.-M.); (S.W.); (R.I.); (Y.M.); (Y.M.); (T.K.); (T.S.); (H.M.)
| | - Rei Ishihara
- Department of Laboratory Science, Gunma University Graduate School of Health Science, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (K.H.); (Y.K.); (K.K.-M.); (S.W.); (R.I.); (Y.M.); (Y.M.); (T.K.); (T.S.); (H.M.)
| | - Yuki Murakami
- Department of Laboratory Science, Gunma University Graduate School of Health Science, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (K.H.); (Y.K.); (K.K.-M.); (S.W.); (R.I.); (Y.M.); (Y.M.); (T.K.); (T.S.); (H.M.)
| | - Yuta Masuda
- Department of Laboratory Science, Gunma University Graduate School of Health Science, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (K.H.); (Y.K.); (K.K.-M.); (S.W.); (R.I.); (Y.M.); (Y.M.); (T.K.); (T.S.); (H.M.)
| | - Ken-ichi Tahara
- Department of Hematology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (N.K.); (K.-i.T.); (H.T.)
| | - Hisashi Takei
- Department of Hematology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (N.K.); (K.-i.T.); (H.T.)
| | - Tetsuhiro Kasamatsu
- Department of Laboratory Science, Gunma University Graduate School of Health Science, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (K.H.); (Y.K.); (K.K.-M.); (S.W.); (R.I.); (Y.M.); (Y.M.); (T.K.); (T.S.); (H.M.)
| | - Takayuki Saitoh
- Department of Laboratory Science, Gunma University Graduate School of Health Science, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (K.H.); (Y.K.); (K.K.-M.); (S.W.); (R.I.); (Y.M.); (Y.M.); (T.K.); (T.S.); (H.M.)
| | - Hirokazu Murakami
- Department of Laboratory Science, Gunma University Graduate School of Health Science, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan; (K.H.); (Y.K.); (K.K.-M.); (S.W.); (R.I.); (Y.M.); (Y.M.); (T.K.); (T.S.); (H.M.)
| |
Collapse
|
9
|
Gotoh N, Minato Y, Saitoh T, Takahashi N, Kasamatsu T, Souma K, Oda T, Hoshino T, Sakura T, Ishizaki T, Shimizu H, Takizawa M, Yokohama A, Tsukamoto N, Handa H, Murakami H. PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes. Eur J Haematol 2020; 104:526-537. [PMID: 32003046 DOI: 10.1111/ejh.13393] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Revised: 01/26/2020] [Accepted: 01/28/2020] [Indexed: 12/12/2022]
Abstract
OBJECTIVE Myelodysplastic syndromes (MDS), caused by various genetic mutations in hematopoietic stem cells, are associated with highly variable outcomes. Poly (ADP-ribose) polymerase-1 (PARP1) plays an important role in DNA damage repair and contributes to the progression of several types of cancer. Here, we investigated the impact of PARP1 V762A polymorphism on the susceptibility to and prognosis of MDS. METHODS Samples collected from 105 MDS patients and 202 race-matched healthy controls were subjected to polymerase chain reaction-restriction fragment length polymorphism for genotyping. RESULTS The allele and genotype frequencies of PARP1 V762A did not differ between MDS patients and the control group. However, MDS patients with the PARP1 V762A non-AA genotype, which is associated with high gene activity, had shorter overall survival rates (P = .01) than those with the AA genotype. Multivariate analysis of overall survival also revealed PARP1 V762A non-AA genotype as a poor prognostic factor (P = .02). When patients were analyzed according to treatment history, the PARP1 V762A non-AA genotype was only associated with poor survival in patients who had received treatment (P = .02). CONCLUSION PARP1 V762A polymorphism may be an independent prognostic factor for MDS, and a predictive biomarker for MDS treatment.
Collapse
Affiliation(s)
- Nanami Gotoh
- Graduate School of Health Sciences, Gunma University, Gunma, Japan
| | - Yusuke Minato
- Department of Virology and Preventive Medicine, Gunma University Graduate School of Medicine, Gunma, Japan.,Department of Anatomy and Cell Biology, Hyogo College of Medicine, Hyogo, Japan
| | - Takayuki Saitoh
- Graduate School of Health Sciences, Gunma University, Gunma, Japan
| | | | | | - Kana Souma
- Graduate School of Health Sciences, Gunma University, Gunma, Japan
| | - Tsukasa Oda
- Laboratory of Molecular Genetics, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan
| | - Takumi Hoshino
- Leukemia Research Center, Saiseikai Maebashi Hospital, Gunma, Japan
| | - Toru Sakura
- Leukemia Research Center, Saiseikai Maebashi Hospital, Gunma, Japan
| | - Takuma Ishizaki
- Department of Hematology, Gunma University Graduate School of Medicine, Gunma, Japan
| | - Hiroaki Shimizu
- Department of Hematology, Gunma University Graduate School of Medicine, Gunma, Japan
| | - Makiko Takizawa
- Department of Hematology, Gunma University Graduate School of Medicine, Gunma, Japan
| | - Akihiko Yokohama
- Division of Blood Transfusion Service, Gunma University Hospital, Gunma, Japan
| | | | - Hiroshi Handa
- Department of Hematology, Gunma University Graduate School of Medicine, Gunma, Japan
| | | |
Collapse
|
10
|
Kasamatsu T, Awata M, Ishihara R, Murakami Y, Gotoh N, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Saitoh T, Murakami H. PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma. Clin Exp Med 2020; 20:51-62. [PMID: 31620907 DOI: 10.1007/s10238-019-00585-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Accepted: 10/05/2019] [Indexed: 12/18/2022]
Abstract
Single-nucleotide polymorphisms (SNPs) of the programmed cell death protein-1 (PDCD1), programmed cell death protein-1 ligand-1 (PDCD1LG1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA4) genes are implicated in the pathogenesis of some cancers. We investigated the role of PDCD1, PDCD1LG1, and CTLA4 SNPs in MM pathogenesis and the susceptibility to and clinical features of multiple myeloma (MM). We obtained genomic DNA from 124 patients with MM and 211 healthy controls and detected PDCD1 (rs36084323, rs41386349, and rs2227982), PDCD1LG1 (rs2297136 and rs4143815), and CTLA4 (rs733618, rs11571316, rs231775, and rs3087243) genotypes using the polymerase chain reaction-restriction fragment length polymorphism method or the TaqMan allelic discrimination real-time PCR method. The patients with MM had a significantly higher frequency of the PDCD1 GCC/GCC haplotype (rs36084323/rs41386349/rs2227982) compared with the healthy controls. PDCD1 rs2227982 CC genotype was associated significantly with a higher frequency of bone lesions. Patients with PDCD1LG1 rs2297136 TT and TC types (high-expression types) showed lower albumin level than those with CC genotype. In addition, the PDCD1LG1 rs4143815 CC and CG types (high-expression types) were associated significantly with higher frequency of patients who were treated with thalidomide and/or bortezomib. However, there was no statistical significance between CTLA4 polymorphisms and clinical variables of patients with MM. There were no significant differences between all the polymorphisms and OS. Our study indicates that the PDCD1 haplotype is associated with a susceptibility to MM. The PDCD1 rs2227982 and PDCD1LG1 rs2297136 affect the clinical features of multiple myeloma patients.
Collapse
Affiliation(s)
- Tetsuhiro Kasamatsu
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan.
| | - Maaya Awata
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan
| | - Rei Ishihara
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan
| | - Yuki Murakami
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan
| | - Nanami Gotoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan
| | - Morio Matsumoto
- Department of Hematology, National Hospital Organization Shibukawa Medical Center, 383 Shirai, Shibukawa, Gunma, 377-0280, Japan
| | - Morio Sawamura
- Department of Hematology, National Hospital Organization Shibukawa Medical Center, 383 Shirai, Shibukawa, Gunma, 377-0280, Japan
| | - Akihiko Yokohama
- Blood Transfusion Service, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan
| | - Hiroshi Handa
- Department of Hematology, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma, 371-0034, Japan
| | - Norifumi Tsukamoto
- Oncology Center, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan
| | - Takayuki Saitoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan
| | - Hirokazu Murakami
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan
- Gunma University of Health and Welfare, 191-1 Kawamagari-cho, Maebashi, Gunma, 371-0823, Japan
| |
Collapse
|
11
|
Murakami H, Kasamatsu T, Murakami J, Kiguchi T, Kanematsu T, Ogawa D, Takamatsu H, Handa H, Ozaki S, Miki H, Takahashi T, Takeo T, Yamauchi T, Morishita T, Kosugi H, Shimizu K. Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study). Int J Hematol 2019; 109:409-417. [PMID: 30701467 DOI: 10.1007/s12185-019-02607-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Revised: 01/20/2019] [Accepted: 01/23/2019] [Indexed: 10/27/2022]
Abstract
A prospective, multicenter, phase II study was performed to assess the efficacy and safety of thalidomide maintenance therapy at different doses in Japanese multiple myeloma (MM) patients. This study included 34 patients (median age, 74 years) who were previously treated with not more than three prior therapies and whose response status was evaluated as at least stable disease. They were randomized into Group A (no maintenance; 12 patients), Group B (50 mg thalidomide maintenance; 12 patients), and Group C (100 mg thalidomide maintenance; 10 patients), respectively. Thalidomide maintenance therapy resulted in improved depth of response in three cases (13.6%) and sustained response after induction therapy in eight cases (36.4%). Two-year progression-free survival (PFS) was 25.0%, 33.3%, and 77.8% in Groups A, B, and C, respectively, and was significantly higher in Group C than in Group A (p = 0.005). There was no difference in the incidence of hematological or non-hematological adverse events between Groups B and C. The current study demonstrates that maintenance with daily thalidomide at 100 mg, but not 50 mg, improved depth of response and prolonged PFS, and that this treatment was feasible for use in Japanese MM patients.
Collapse
Affiliation(s)
- Hirokazu Murakami
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan.
| | - Tetsuhiro Kasamatsu
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | - Jun Murakami
- Department of Hematology, Toyama University Hospital, Toyama, Japan
| | - Toru Kiguchi
- Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan
| | - Takeshi Kanematsu
- Department of Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan
| | - Daisuke Ogawa
- Department of Hematology, Nagasaki Prefectural Shimabara Hospital, Shimabara, Japan
| | | | - Hiroshi Handa
- Department of Hematology, Gunma University, Maebashi, Japan
| | - Shuji Ozaki
- Department of Hematology, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Hirokazu Miki
- Division of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, Tokushima, Japan
| | | | - Takaaki Takeo
- Department of Hematology, Yokkaichi Municipal Hospital, Yokkaichi, Japan
| | - Tatsuya Yamauchi
- Department of Hematology, Toki Municipal General Hospital, Toki, Japan
| | - Takanobu Morishita
- Department of Hematology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan
| | - Hiroshi Kosugi
- Department of Hematology, Ogaki Municipal Hospital, Ogaki, Japan
| | - Kazuyuki Shimizu
- Department of Hematology/Oncology, Higashi Nagoya National Hospital, Nagoya, Japan
| |
Collapse
|
12
|
Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma. Hematol Oncol 2018; 36:792-800. [PMID: 30176173 DOI: 10.1002/hon.2559] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2018] [Revised: 08/24/2018] [Accepted: 08/30/2018] [Indexed: 01/06/2023]
Abstract
The international staging system (ISS) is the most commonly used risk-stratification system for patients with multiple myeloma (MM) and is determined by serum albumin and β2-microglobulin levels. In the two determinants, β2-microglobulin levels are frequently observed to be elevated in patients with myeloma, particularly in those with renal impairment. In comparison with patients with intact immunoglobulin myeloma, patients with LC myeloma do not necessarily show decreased levels of serum albumin. The clinical impact of ISS in patients with LCMM, in particular the distinction between ISS I and II, may be complicated due to non-decreased levels of serum albumin in both stages. Accordingly, we have attempted to assess clinical relevance of the ISS in patients with LC myeloma. The clinical data of 1899 patients with MM diagnosed between January 2001 and December 2012 were collected from 38 affiliated hospitals of the Japanese Society of Myeloma. Significant difference was not found between stage I (n = 72) and stage II (n = 92) in LC myeloma patients (n = 307). The mean serum albumin concentration of patients with LC myeloma was within the reference range but higher than that of patients with IgG + IgA myeloma (n = 1501), which complicates the distinction between ISS stage I and II myeloma. Patients with LC myeloma had low frequencies of t(4; 14) and high frequency of elevated lactate dehydrogenase, and despite a relevant amount of missing data in our registry (R-ISS stage I; n = 11, stage II; n = 32, and stage III: n = 18), the information included in the R-ISS scoring system seems to be more accurate than ISS to obtain a reliable risk stratification approach in non-ISS stage III LC myeloma patients.
Collapse
Affiliation(s)
- Tetsuhiro Kasamatsu
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | - Shuji Ozaki
- Department of Hematology, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Takayuki Saitoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | - Jun Konishi
- Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Kazutaka Sunami
- Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Mitsuhiro Itagaki
- Department of Hematology, Hiroshima Red Cross Hospital, Hiroshima, Japan
| | - Hideki Asaoku
- Department of Hematology, Hiroshima Red Cross Hospital, Hiroshima, Japan
| | - Takaaki Cho
- Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
| | - Hiroshi Handa
- Department of Hematology, Gunma University, Maebashi, Japan
| | - Shotaro Hagiwara
- Division of Hematology, Department of Internal Medicine, National Medical Center for Global Health and Medicine, Tokyo, Japan
| | - Toshio Wakayama
- Department of Hematology, Shimane Prefectural Central Hospital, Izumo, Japan
| | - Akiko Negoro
- Department of Hematology, Japan Labor Health and Welfare Organization Yokohama Rosai Hospital, Yokohama, Japan
| | - Naoki Takezako
- Department of Hematology, National Hospital Organization National Disaster Medical Center, Tokyo, Japan
| | - Naoko Harada
- Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan
| | - Yoshiaki Kuroda
- Department of Hematology, Hiroshima University Hospital, Hiroshima, Japan
| | - Chiaki Nakaseko
- Department of Hematology, Chiba University Hospital, Chiba, Japan
| | - Takaaki Miyake
- Department of Oncology/Hematology, Shimane University Hospital, Izumo, Japan
| | - Nobumasa Inoue
- Department of Internal Medicine, National Hospital Organization Osaka Medical Center, Osaka, Japan
| | - Hiroyuki Hata
- Department of Immunology and Hematology, Faculty of Life Sciences, Graduate School of Health Sciences, Kumamoto University, Kumamoto, Japan
| | - Chihiro Shimazaki
- Department of Hematology, Japan Community Healthcare Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan
| | - Tatsuharu Ohno
- Division of Hematology and Immunology, Department of Internal Medicine, Ohtsu Red Cross Hospital, Ohtsu, Japan
| | - Junya Kuroda
- Department of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Tohru Murayama
- Department of Hematology, Hyogo Cancer Center, Akashi, Japan
| | - Takahiro Kobayashi
- Department of Hematology, Nephrology and Rheumatology, Akita University Hospital, Akita, Japan
| | - Masahiro Abe
- Department of Hematology, Tokushima University Hospital, Tokushima, Japan
| | - Tadao Ishida
- Department of Gastroenterology, Rheumatology, and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan
| | - Eiich Nagura
- Department of Hematology, Chutoen General Medical Center, Kakegawa, Japan
| | - Kazuyuki Shimizu
- Department of Hematology/Oncology, Higashi Nagoya National Hospital, Nagoya, Japan
| |
Collapse
|
13
|
Gotoh N, Saitoh T, Takahashi N, Kasamatsu T, Minato Y, Lobna A, Oda T, Hoshino T, Sakura T, Shimizu H, Takizawa M, Handa H, Yokohama A, Tsukamoto N, Murakami H. Association between OGG1 S326C CC genotype and elevated relapse risk in acute myeloid leukemia. Int J Hematol 2018; 108:246-253. [PMID: 29737460 DOI: 10.1007/s12185-018-2464-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Revised: 04/24/2018] [Accepted: 04/25/2018] [Indexed: 11/28/2022]
Abstract
Recent studies have shown that tumors of relapsed acute myeloid leukemia (AML) present additional genetic mutations compared to the primary tumors. The base excision repair (BER) pathway corrects oxidatively damaged mutagenic bases and plays an important role in maintaining genetic stability. The purpose of the present study was to investigate the relationship between BER functional polymorphisms and AML relapse. We focused on five major polymorphisms: OGG1 S326C, MUTYH Q324H, APE1 D148E, XRCC1 R194W, and XRCC1 R399Q. Ninety-four adults with AML who achieved first complete remission were recruited. Genotyping was performed with the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The OGG1 S326C CC genotype (associated with lower OGG1 activity) was observed more frequently in patients with AML relapse [28.9 vs. 8.9%, odds ratio (OR) = 4.10, 95% confidence interval (CI) = 1.35-12.70, P = 0.01]. Patients with the CC genotype exhibited shorter relapse-free survival (RFS). Moreover, the TCGA database suggested that low OGG1 expression in AML cells is associated with a higher frequency of mutations. The present findings suggest that the OGG1 S326C polymorphism increased the probability of AML relapse and may be useful as a prognostic factor for AML relapse risk.
Collapse
Affiliation(s)
- Nanami Gotoh
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan
| | - Takayuki Saitoh
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan.
| | - Noriyuki Takahashi
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan
| | - Tetsuhiro Kasamatsu
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan
| | - Yusuke Minato
- Department of Virology and Preventive Medicine, Gunma University Graduate School of Medicine, Gunma, Japan
| | - Alkebsi Lobna
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan
| | - Tsukasa Oda
- Laboratory of Molecular Genetics, Institute for Molecular and Cellular Regulation, Gunma University, Gunma, Japan
| | - Takumi Hoshino
- Leukemia Research Center, Saiseikai Maebashi Hospital, Gunma, Japan
| | - Toru Sakura
- Leukemia Research Center, Saiseikai Maebashi Hospital, Gunma, Japan
| | | | - Makiko Takizawa
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan
| | - Hiroshi Handa
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan
| | - Akihiko Yokohama
- Division of Blood Transfusion Service, Gunma University Hospital, Gunma, Japan
| | | | - Hirokazu Murakami
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8514, Japan
| |
Collapse
|
14
|
Kasamatsu T, Ino R, Takahashi N, Gotoh N, Minato Y, Takizawa M, Yokohama A, Handa H, Saitoh T, Tsukamoto N, Murakami H. PDCD1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia. Br J Haematol 2018; 180:705-714. [PMID: 29359792 DOI: 10.1111/bjh.15085] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2017] [Accepted: 11/07/2017] [Indexed: 01/23/2023]
Abstract
Programmed death-1 (PD-1, PDCD1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4, CTLA4) play central roles in immune checkpoint pathways. Single nucleotide polymorphisms (SNPs) of PDCD1 and CTLA4 have been reported to be associated with susceptibility to some autoimmune diseases. However, the potential association between SNPs in these immune checkpoint genes and risk of chronic immune thrombocytopenia (cITP) remain controversial and obscure. The aims of this study were to clarify the influence of PDCD1 and CTLA4 SNPs on the risk of developing cITP and its clinical features. We obtained genomic DNA from 119 patients with cITP and 223 healthy controls; their genotypes were determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Patients with cITP had a significantly higher frequency of the PDCD1 +7209 TT genotype compared with healthy controls. The CTLA4 -1577 GG genotype and CT60 GG genotype showed higher frequencies of platelet count <5 × 109 /l at diagnosis, minimum platelet count <5 × 109 /l, and bleeding symptoms. Moreover, the PDCD1 -606 AA genotype and +63379 TT genotype were significantly associated with a lower number of patients who achieved a complete response to prednisolone treatment. Our results suggest that the immune checkpoint polymorphisms may affect the susceptibility to the clinical features of cITP, and treatment response of the affected patients.
Collapse
Affiliation(s)
- Tetsuhiro Kasamatsu
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | - Rumi Ino
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | - Noriyuki Takahashi
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | - Nanami Gotoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | - Yusuke Minato
- Department of Anatomy and Cell Biology, Hyogo College of Medicine, Maebashi, Japan
| | - Makiko Takizawa
- Department of Haematology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Akihiko Yokohama
- Blood Transfusion Service, Gunma University Hospital, Maebashi, Japan
| | - Hiroshi Handa
- Department of Haematology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Takayuki Saitoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| | | | - Hirokazu Murakami
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan
| |
Collapse
|
15
|
Kasamatsu T, Kimoto M, Takahashi N, Minato Y, Gotoh N, Takizawa M, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Saitoh T, Murakami H. IL17A
and IL23R
gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma. Hematol Oncol 2017; 36:196-201. [DOI: 10.1002/hon.2469] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Revised: 06/29/2017] [Accepted: 07/12/2017] [Indexed: 01/19/2023]
Affiliation(s)
- Tetsuhiro Kasamatsu
- Department of Laboratory Sciences; Gunma University Graduate School of Health Sciences; Maebashi Gunma Japan
| | - Mari Kimoto
- Department of Laboratory Sciences; Gunma University Graduate School of Health Sciences; Maebashi Gunma Japan
| | - Noriyuki Takahashi
- Department of Laboratory Sciences; Gunma University Graduate School of Health Sciences; Maebashi Gunma Japan
| | - Yusuke Minato
- Department of Anatomy and Cell Biology; Hyogo College of Medicine; Nishinomiya Hyogo Japan
| | - Nanami Gotoh
- Department of Laboratory Sciences; Gunma University Graduate School of Health Sciences; Maebashi Gunma Japan
| | - Makiko Takizawa
- Department of Hematology; Gunma University Graduate School of Medicine; Maebashi Gunma Japan
| | - Morio Matsumoto
- National Hospital Organization; Shibukawa Medical Center; Shibukawa Gunma Japan
| | - Morio Sawamura
- National Hospital Organization; Shibukawa Medical Center; Shibukawa Gunma Japan
| | - Akihiko Yokohama
- Blood Transfusion Service; Gunma University Hospital; Maebashi Gunma Japan
| | - Hiroshi Handa
- Department of Hematology; Gunma University Graduate School of Medicine; Maebashi Gunma Japan
| | | | - Takayuki Saitoh
- Department of Laboratory Sciences; Gunma University Graduate School of Health Sciences; Maebashi Gunma Japan
| | - Hirokazu Murakami
- Department of Laboratory Sciences; Gunma University Graduate School of Health Sciences; Maebashi Gunma Japan
| |
Collapse
|
16
|
Handa H, Kuroda Y, Kimura K, Masuda Y, Hattori H, Alkebsi L, Matsumoto M, Kasamatsu T, Kobayashi N, Tahara KI, Takizawa M, Koiso H, Ishizaki T, Shimizu H, Yokohama A, Tsukamoto N, Saito T, Murakami H. Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma. Br J Haematol 2017; 179:449-460. [PMID: 28770558 DOI: 10.1111/bjh.14882] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2017] [Accepted: 06/30/2017] [Indexed: 12/28/2022]
Abstract
Extramedullary myeloma (EMM) occurs when myeloma develops outside the bone marrow; it often develops after chemotherapy and is associated with the acquisition of chemo-resistance and a fatal course. The mechanisms underlying extramedullary spread have not yet been fully elucidated. MALAT1 is a highly abundantly and ubiquitously expressed long non-coding RNA that plays important roles in cancer metastasis. The aims of this study were to clarify the association of MALAT1 with EMM and to elucidate the underlying mechanism of EMM formation under chemotherapeutic pressure. MALAT1 expression was significantly higher in multiple myeloma (MM) than in monoclonal gammopathy of undetermined significance. Furthermore, MALAT1 expression was markedly higher in EMM compared with that in corresponding intramedullary myeloma cells. A higher MALAT1 level was associated with shorter overall and progression-free survival. MALAT1 expression level was positively correlated with expression of HSP90AA1, HSP90AB1 and HSP90B1 but not with TP53 expression. MALAT1 was significantly upregulated by bortezomib and doxorubicin. Considering the known functions of MALAT1, our results suggest that it acts as a stress response gene that is upregulated by chemotherapy, thereby linking chemotherapy to EMM formation. Elucidating the biological implication of long non-coding RNA contributes to deeper understanding concerning the pathogenesis and investigation of novel therapeutic targets for MM.
Collapse
Affiliation(s)
- Hiroshi Handa
- Department of Haematology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Yuko Kuroda
- Gunma University Graduate School of Health Science, Maebashi, Japan
| | - Kei Kimura
- Gunma University Graduate School of Health Science, Maebashi, Japan
| | - Yuta Masuda
- Gunma University Graduate School of Health Science, Maebashi, Japan
| | - Hikaru Hattori
- Gunma University Graduate School of Health Science, Maebashi, Japan
| | - Lobna Alkebsi
- Gunma University Graduate School of Health Science, Maebashi, Japan
| | - Morio Matsumoto
- National Hospital Organization Shibukawa Medical Centre, Shibukawa, Japan
| | | | - Nobuhiko Kobayashi
- National Hospital Organization Shibukawa Medical Centre, Shibukawa, Japan
| | - Ken-Ichi Tahara
- National Hospital Organization Shibukawa Medical Centre, Shibukawa, Japan
| | - Makiko Takizawa
- Department of Haematology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Hiromi Koiso
- Department of Haematology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Takuma Ishizaki
- Department of Haematology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Hiroaki Shimizu
- Department of Haematology, Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Akihiko Yokohama
- Blood Transfusion Service, Gunma University Hospital, Maebashi, Japan
| | | | - Takayuki Saito
- Gunma University Graduate School of Health Science, Maebashi, Japan
| | | |
Collapse
|
17
|
Handa H, Sasaki Y, Hattori H, Alkebsi L, Kasamatsu T, Saitoh T, Mitsui T, Yokohama A, Tsukamoto N, Matsumoto M, Murakami H. Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance. Oncol Lett 2017; 14:4372-4378. [PMID: 28943951 DOI: 10.3892/ol.2017.6672] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Accepted: 03/03/2017] [Indexed: 11/05/2022] Open
Abstract
The putative tumor suppressor gene WW domain containing oxidoreductase (WWOX) spans a common fragile site (CFS) on chromosome 16q23.3. CFSs are regions of profound genomic instability and sites for genomic deletions in cancer cells. Therefore, WWOX is structurally altered in diverse nonhematological cancer types. However, the function of WWOX in hematological tumor types, including multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) remains unclear. WWOX expression and methylation in patients with MM, MGUS, or noninvasive lymphoma (control) were analyzed using reverse transcription- and methylation specific-polymerase chain reaction analysis. Variant WWOX transcripts were detected in 65 and 50% of patients with MM and MGUS, respectively, compared with 10% of controls. WWOX expression was higher in patients with MM, and WWOX promoter methylation was detected in 35% of patients with MM compared with 5% of patients with MGUS and 4% of controls. WWOX promoter methylation was significantly associated with shorter overall survival time of patients, in particular those with MM who were never treated with novel agents. Genomic alterations, including deletions and promoter methylation that affect WWOX expression occur early and may be involved in the pathogenesis, progression, and prognosis of MM.
Collapse
Affiliation(s)
- Hiroshi Handa
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
| | - Yoshiko Sasaki
- Department of Laboratory Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
| | - Hikaru Hattori
- Department of Laboratory Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
| | - Lobna Alkebsi
- Department of Laboratory Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
| | - Tetsuhiro Kasamatsu
- Department of Laboratory Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
| | - Takayuki Saitoh
- Department of Laboratory Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
| | - Takeki Mitsui
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
| | - Akihiko Yokohama
- Blood Transfusion Service, Gunma University Hospital, Maebashi, Gunma 371-8511, Japan
| | - Norifumi Tsukamoto
- Oncology Center, Gunma University Hospital, Maebashi, Gunma 371-8511, Japan
| | - Morio Matsumoto
- Department of Hematology, National Hospital Organization Shibukawa Medical Center, Shibukawa, Gunma 377-0280, Japan
| | - Hirokazu Murakami
- Department of Laboratory Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
| |
Collapse
|
18
|
Takahashi N, Saitoh T, Gotoh N, Nitta Y, Alkebsi L, Kasamatsu T, Minato Y, Yokohama A, Tsukamoto N, Handa H, Murakami H. The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP. BMC Immunol 2017; 18:26. [PMID: 28511637 PMCID: PMC5434613 DOI: 10.1186/s12865-017-0210-3] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Accepted: 04/21/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND T-helper cell type 1 (Th1) polarization in chronic immune thrombocytopenia (cITP) has been reported at the protein and mRNA levels. We evaluated the impact of Th1/Th2 cytokine and cytokine receptor functional polymorphisms on both susceptibility to, and severity of, cITP. We analysed IFN-γ + 874 T/A, IFN-γR -611G/A, IL-4 -590C/T, and IL-4Rα Q576R polymorphisms in 126 cITP patients (male/female: 34/92; median age: 47.7 years) and 202 healthy control donors. Genotyping was determined by PCR and direct sequencing. The Th1/Th2 ratio was detected in peripheral blood mononuclear cells via flow cytometry. RESULTS cITP patients had a higher frequency of the IL-4Rα 576 non-QQ genotype compared to healthy subjects (P = 0.04). cITP patients with the IFN-γ +874 non-AA genotype (high expression type) showed more severe thrombocytopenia than those with the AA genotype (P < 0.05). cITP patients had a significantly higher Th1/Th2 ratio than control patients (P < 0.01); this ratio was inversely correlated with platelet counts. Furthermore, patients with both IFN-γ +874 non-AA genotype (high expression type) and IFN-γR -611 non-AA genotype (high-function type) had a significantly higher Th1/Th2 ratio (P < 0.05). CONCLUSIONS The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Cells, Cultured
- Child
- Child, Preschool
- Chronic Disease
- Female
- Genetic Predisposition to Disease
- Genotype
- Humans
- Interferon-gamma/genetics
- Interferon-gamma/metabolism
- Interleukin-4/genetics
- Interleukin-4/metabolism
- Interleukin-4 Receptor alpha Subunit/genetics
- Interleukin-4 Receptor alpha Subunit/metabolism
- Male
- Middle Aged
- Polymorphism, Single Nucleotide
- Purpura, Thrombocytopenic, Idiopathic/genetics
- Purpura, Thrombocytopenic, Idiopathic/immunology
- Receptors, Interferon/genetics
- Receptors, Interferon/metabolism
- Th1 Cells/immunology
- Th1-Th2 Balance/genetics
- Th2 Cells/immunology
- Young Adult
- Interferon gamma Receptor
Collapse
Affiliation(s)
- Noriyuki Takahashi
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma 371-8514 Japan
| | - Takayuki Saitoh
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma 371-8514 Japan
| | - Nanami Gotoh
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma 371-8514 Japan
| | - Yasuhiro Nitta
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma 371-8514 Japan
| | - Lobna Alkebsi
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma 371-8514 Japan
| | - Tetsuhiro Kasamatsu
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma 371-8514 Japan
| | - Yusuke Minato
- Department of Virology and Preventive Medicine, Gunma University, Gunma, Japan
| | - Akihiko Yokohama
- Division of Blood Transfusion Service, Gunma University Hospital, Gunma, Japan
| | | | - Hiroshi Handa
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan
| | - Hirokazu Murakami
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma 371-8514 Japan
| |
Collapse
|
19
|
Kasamatsu T, Saitoh T, Ino R, Gotoh N, Mitsui T, Shimizu H, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Murakami H. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib. Hematol Oncol 2016; 35:711-718. [PMID: 27405747 DOI: 10.1002/hon.2322] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 05/02/2016] [Accepted: 05/27/2016] [Indexed: 11/09/2022]
Abstract
Interleukin-10 (IL-10) and IL-10 receptor (IL-10R) single nucleotide polymorphisms have been implicated in the pathogenesis of many cancers. We investigated the influence of IL-10 -592C/A, IL-10RA I224V, and IL-10RB K47E on the risk of developing multiple myeloma (MM) and the clinical features of MM. We extracted the genomic DNA from 128 MM patients and 202 healthy controls and used polymerase chain reaction-restriction fragment length polymorphism method to detect IL-10 promoter -592C/A (rs1800872), IL-10RA (rs2228055), and IL-10RB K47E (rs2834167) genotypes. Overall survival (OS) was defined as the interval from the date of diagnosis to the date of death or last clinical appointment. No statistically significant difference was observed in the genotype and allele frequencies of IL-10 -592C/A, IL-10RA I224V, and IL-10RB K47E between MM patients and healthy controls. IL-10RA II genotype was significantly associated with a hemoglobin level lower than that of IV and VV genotypes (mean ± standard deviation, 9.21 ± 2.46 vs 10.3 ± 2.33 g/dL; P = .021). IL-10 -592 AA genotype was significantly associated with OS better than that of CA and CC genotypes (median OS, 74.5 vs 46.3 months; P = .047). We observed significant differences in survival between patients treated with thalidomide and/or bortezomib and those treated with conventional treatments (median OS, 74.5 vs 38.2 months; P = .021). Therefore, we also examined the effect of IL-10 and IL-10R polymorphisms on the clinical variables and OS of patients treated with thalidomide and/or bortezomib. In addition, IL-10RB EE genotype was significantly associated with poorer survival than KK and KE genotypes (median OS, 46.3 vs 78.8 months; P = .015). Our findings indicate that IL-10 and IL-10R gene polymorphisms may not contribute to the susceptibility to MM but may be associated with the severity and prognosis of MM. In particular, IL-10RB K47E polymorphism may contribute to the poor prognosis of MM patients treated with thalidomide and/or bortezomib.
Collapse
Affiliation(s)
- Tetsuhiro Kasamatsu
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Gunma, Japan
| | - Takayuki Saitoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Gunma, Japan
| | - Rumi Ino
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Gunma, Japan
| | - Nanami Gotoh
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Gunma, Japan
| | - Takeki Mitsui
- Department of Medicine and Clinical Science, Gunma University, Maebashi, Gunma, Japan
| | - Hiroaki Shimizu
- Department of Medicine and Clinical Science, Gunma University, Maebashi, Gunma, Japan
| | - Morio Matsumoto
- National Hospital Organization, Nishigunma National Hospital, Shibukawa, Gunma, Japan
| | - Morio Sawamura
- National Hospital Organization, Nishigunma National Hospital, Shibukawa, Gunma, Japan
| | - Akihiko Yokohama
- Blood Transfusion Service, Gunma University Hospital, Maebashi, Gunma, Japan
| | - Hiroshi Handa
- Department of Medicine and Clinical Science, Gunma University, Maebashi, Gunma, Japan
| | | | - Hirokazu Murakami
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Gunma, Japan
| |
Collapse
|
20
|
Murakami H, Saitoh T, Kasamatsu T. [Hematologic Malignancies/Pediatric Malignancies. III. Treatment of Relapsed/Refractory Multiple Myeloma]. Gan To Kagaku Ryoho 2016; 43:539-544. [PMID: 27344682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
|
21
|
Norjmaa B, Saitoh T, Kasamatsu T, Minato Y, Sunaga N, Murakami H. Abstract 3857: The polymorphisms of XRCC1 Arg194Trp and the XRCC1Arg399Gln affect the clinical features and the prognosis of MDS. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-3857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: X-ray repair cross-complementing group 1 (XRCC1) is involved an important role in base excision repair (BER) system of DNA repair. Polymorphism in DNA repair genes may be modified of DNA repair capacity. However, it is unclear that the polymorphisms of XRCC1alter the clinical features of MDS patients. Our study was performed to evaluate the effect of the XRCC1Arg194Trp and the XRCC1Arg399Gln with the susceptibility and clinical features of MDS.
Methods: We genotyped the polymorphisms by using polymerase chain reaction -restriction fragment-length polymorphism (PCR-RFLP) analysis in 119 patients with MDS [median 67.9 years, range 17.1-86.5 years; male/female 81/38; RCUD (n = 40), RARS (n = 6), RCMD (n = 21), MDS-U (n = 13), RAEB-1(n = 14), RAEB-2 (n = 12), others (n = 13)] and 202-health controls.
Results: In the allele and genotype frequencies of the XRCC1Arg194Trp and the XRCC1Arg399Gln were not statistically significant difference in patients and the controls. However, Arg/Arg genotypes of XRCC1 194 and the XRCC1 399 were significantly associated with lower Hb. In addition, XRCC1 399 non Arg/Arg genotype was significantly associated with previous history of radiotherapy and multiple cancers. Furthermore, XRCC1Arg194Trp non Arg/Arg genotype and XRCC1Arg399Gln Arg/Arg genotype were significantly associated with poor prognosis of MDS patients.
Conclusion: We found that the polymorphisms of XRCC1 may be affected the clinical features and the prognosis of MDS.
Citation Format: Batchimeg Norjmaa, Takayuki Saitoh, Tetsuhiro Kasamatsu, Yusuke Minato, Noriaki Sunaga, Hirokazu Murakami. The polymorphisms of XRCC1 Arg194Trp and the XRCC1Arg399Gln affect the clinical features and the prognosis of MDS. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3857. doi:10.1158/1538-7445.AM2015-3857
Collapse
Affiliation(s)
- Batchimeg Norjmaa
- 1Department of Laboratory Sciences, Gunma Graduate School of Health Sciences, Maebashi, Gunma, Japan
| | - Takayuki Saitoh
- 1Department of Laboratory Sciences, Gunma Graduate School of Health Sciences, Maebashi, Gunma, Japan
| | - Tetsuhiro Kasamatsu
- 1Department of Laboratory Sciences, Gunma Graduate School of Health Sciences, Maebashi, Gunma, Japan
| | - Yusuke Minato
- 2Department of Virology and Preventive Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
| | - Noriaki Sunaga
- 3Onclogy Center, Gunma University Hospital, Maebashi, Gunma, Japan
| | - Hirokazu Murakami
- 1Department of Laboratory Sciences, Gunma Graduate School of Health Sciences, Maebashi, Gunma, Japan
| |
Collapse
|
22
|
Kasamatsu T, Saitoh T, Minato Y, Shimizu H, Yokohama A, Tsukamoto N, Handa H, Sakura T, Murakami H. Polymorphisms of IL-10 affect the severity and prognosis of myelodysplastic syndrome. Eur J Haematol 2015; 96:245-51. [DOI: 10.1111/ejh.12577] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/30/2015] [Indexed: 12/16/2022]
Affiliation(s)
- Tetsuhiro Kasamatsu
- Department of Laboratory Sciences; Gunma University Graduate School of Health Sciences; Maebashi Japan
| | - Takayuki Saitoh
- Department of Laboratory Sciences; Gunma University Graduate School of Health Sciences; Maebashi Japan
| | - Yusuke Minato
- Department of Virology and Preventive Medicine; Gunma Graduate School of Medicine; Maebashi Japan
| | - Hiroaki Shimizu
- Department of Medicine and Clinical Science; Gunma University; Maebashi Japan
| | - Akihiko Yokohama
- Blood Transfusion Service; Gunma University Hospital; Maebashi Japan
| | | | - Hiroshi Handa
- Department of Medicine and Clinical Science; Gunma University; Maebashi Japan
| | - Toru Sakura
- Leukemia Research Center; Saiseikai Maebashi Hospital; Maebashi Japan
| | - Hirokazu Murakami
- Department of Laboratory Sciences; Gunma University Graduate School of Health Sciences; Maebashi Japan
| |
Collapse
|
23
|
Arimoto T, Kawana K, Adachi K, Ikeda Y, Nagasaka K, Tsuruga T, Yamashita A, Oda K, Ishikawa M, Kasamatsu T, Onda T, Konishi I, Yoshikawa H, Yaegashi N. Minimization of curative surgery for treatment of early cervical cancer: a review. Jpn J Clin Oncol 2015; 45:611-6. [DOI: 10.1093/jjco/hyv048] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2014] [Accepted: 03/10/2015] [Indexed: 11/14/2022] Open
|
24
|
Suto C, Murakami H, Kobayashi Y, Nagamine T, Saitoh T, Kasamatsu T, Ogawara H, Murakami M. High Frequency of Hepatitis B Core and Surface Antibodies in Hepatitis C Virus-Infected Patients on the Screening Examination. Rinsho Byori 2015; 63:305-311. [PMID: 26524852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
BACKGROUND Hepatitis B virus (HBV) and hepatitis C virus (HCV) are important human pathogens that cause chronic liver disease and hepatocellular carcinoma. Co-infection of HBV and HCV is not uncommon, particularly in countries where these two viruses are endemic. Therefore, the characteristics of HBV co-infection in HCV antibody (HCVAb) -positive Japanese patients found on the screening examination were analyzed. PATIENTS AND METHODS Between January and December 2011, HCVAb status was evaluated as the screening examination in 12,582 patients in Gunma University Hospital, and it was positive in 402 patients (3.2%). In 331 HCVAb-positive/HBs antigen (HBsAg) -negative patients with available residual serum, HBs antibody (HBsAb) and HBc antibody (HBcAb) were examined. In addition, HCV-RNA was examined in 291 patients with available residual serum. HBV-DNA and HBV core-related antigen (HBcrAg) were examined in 106 patients with available residual serum. RESULTS The HCVAb titer was distributed between 1 and 18 sample/cutoff index (S/CO). 275 patients (83.1%) had a high HCVAb titer (S/CO ≥10). HCV-RNA was positive in 230 (79.0%) patients, and it was more frequently detected in HCVAb high-titer patients (88%) than in low-titer patients (32%; p < 0.0001); 61 (18.4%) and 101(30.5%) patients were positive for HBsAb and HBcAb, respectively. Of 230 HCV-RNA-positive patients, 38 (16.5%) and 59 (25.6%) were positive for HBsAb and HBcAb, respectively. Three (2.8%) and 2 (1.9%) of 106 patients had HBV-DNA and HBVCrAg. The ALT level was higher than 30 IU/L in 146/327 (44.6%) HCVAb-positive patients who had ALT levels measured. Abnormal ALT elevation was more frequent in HCVAb high-titer patients than in low-titer patients (48.3% vs. 26.8%; p = 0.0031), and in HCV-RNA-positive patients than in HCV-RNA-negative patients (54.2% vs. 13.3%; p < 0.001). CONCLUSION HBV reactivation should be noted in these HCVAb-positive/HBsAg-negative patients on the screening examination if these patients must receive chemotherapy or immunosuppressive therapy. In addition, surveying of HBsAb in addition to HBcAb is also necessary.
Collapse
|
25
|
Kunieda F, Kasamatsu T, Arimoto T, Onda T, Toita T, Shibata T, Fukuda H, Kamura T. Non-randomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer: Japan Clinical Oncology Group Study (JCOG1101). Jpn J Clin Oncol 2014; 45:123-6. [DOI: 10.1093/jjco/hyu168] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Nishio S, Mikami Y, Otsuki T, Yaegashi N, Satoh T, Yoshikawa H, Saitoh M, Okamoto A, Kasamatsu T, Miyamoto T, Shiozawa T, Yoshioka Y, Konishi I, Kojima A, Takehara K, Kaneki E, Kobayashi H, Ushijima K, Kamura T. Recurrence Patterns of Gastric-Type Adenocarcinoma (Gas) of the Uterine Cervix: a Subset Analysis of the Gynecologic Cancer Study Group of the Japan Clinical Oncology Group (Jcog) Gas Multicenter Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu338.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Kitaguchi M, Murakami N, Nakamura S, Okamoto H, Inaba K, Morota M, Ito Y, Minako S, Kasamatsu T, Itami J. EP-1350: Comparison of DVH and myelosuppression between IMRT and 3DCRT in cervical cancer with postoperative radiotherapy. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31468-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
28
|
Murakami N, Kasamatsu T, Sumi M, Yoshimura R, Takahashi K, Inaba K, Morota M, Mayahara H, Ito Y, Itami J. Radiation therapy for primary vaginal carcinoma. J Radiat Res 2013; 54:931-937. [PMID: 23559599 PMCID: PMC3766300 DOI: 10.1093/jrr/rrt028] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/09/2012] [Revised: 03/04/2013] [Accepted: 03/05/2013] [Indexed: 06/02/2023]
Abstract
Brachytherapy plays a significant role in the management of cervical cancer, but the clinical significance of brachytherapy in the management of vaginal cancer remains to be defined. Thus, a single institutional experience in the treatment of primary invasive vaginal carcinoma was reviewed to define the role of brachytherapy. We retrospectively reviewed the charts of 36 patients with primary vaginal carcinoma who received definitive radiotherapy between 1992 and 2010. The treatment modalities included high-dose-rate intracavitary brachytherapy alone (HDR-ICBT; two patients), external beam radiation therapy alone (EBRT; 14 patients), a combination of EBRT and HDR-ICBT (10 patients), or high-dose-rate interstitial brachytherapy (HDR-ISBT; 10 patients). The median follow-up was 35.2 months. The 2-year local control rate (LCR), disease-free survival (DFS), and overall survival (OS) were 68.8%, 55.3% and 73.9%, respectively. The 2-year LCR for Stage I, II, III and IV was 100%, 87.5%, 51.5% and 0%, respectively (P = 0.007). In subgroup analysis consisting only of T2-T3 disease, the use of HDR-ISBT showed marginal significance for favorable 5-year LCR (88.9% vs 46.9%, P = 0.064). One patient each developed Grade 2 proctitis, Grade 2 cystitis, and a vaginal ulcer. We conclude that brachytherapy can play a central role in radiation therapy for primary vaginal cancer. Combining EBRT and HDR-ISBT for T2-T3 disease resulted in good local control.
Collapse
Affiliation(s)
- N. Murakami
- Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan
| | - T. Kasamatsu
- Department of Gynecologic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan
| | - M. Sumi
- Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan
| | - R. Yoshimura
- Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan
| | - K. Takahashi
- Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan
| | - K. Inaba
- Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan
| | - M. Morota
- Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan
| | - H. Mayahara
- Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan
| | - Y. Ito
- Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan
| | - J. Itami
- Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, Japan
| |
Collapse
|
29
|
Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T, Yasugi T, Yaegashi N, Yokota H, Kodama S, Mizunoe T, Hiura M, Kasamatsu T, Shibata T, Kamura T. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer 2013; 108:1957-63. [PMID: 23640393 PMCID: PMC3671094 DOI: 10.1038/bjc.2013.179] [Citation(s) in RCA: 82] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background: A phase III trial was conducted to determine whether neoadjuvant chemotherapy (NACT) before radical surgery (RS) improves overall survival. Methods: Patients with stage IB2, IIA2, or IIB squamous cell carcinoma of the uterine cervix were randomly assigned to receive either BOMP (bleomycin 7 mg days 1–5, vincristine 0.7 mg m−2 day 5, mitomycin 7 mg m−2 day 5, cisplatin 14 mg m−2 days 1–5, every 3 weeks for 2 to 4 cycles) plus RS (NACT group) or RS alone (RS group). Patients with pathological high-risk factors received postoperative radiotherapy (RT). The primary end point was overall survival. Results: A total of 134 patients were randomly assigned to treatment. This study was prematurely terminated at the first planned interim analysis because overall survival in the NACT group was inferior to that in the RS group. Patients who received postoperative RT were significantly lower in the NACT group (58%) than in the RS group (80% P=0.015). The 5-year overall survival was 70.0% in the NACT group and 74.4% in the RS group (P=0.85). Conclusion: Neoadjuvant chemotherapy with BOMP regimen before RS did not improve overall survival, but reduced the number of patients who received postoperative RT.
Collapse
Affiliation(s)
- N Katsumata
- Department of Medical Oncology, Nippon Medical School Musashikosugi Hospital, Kawasaki, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Murakami N, Kasamatsu T, Takahashi K, Inaba K, Kuroda Y, Morota M, Mayahara H, Ito Y, Sumi M, Itami J. PO-255 HIGH DOSE-RATE INTERSTITIAL BRACHYTHERAPY FOR GYNECOLOGICAL MALIGNANCIES. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)72221-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
31
|
Toita T, Ohno T, Kaneyasu Y, Kato T, Uno T, Hatano K, Norihisa Y, Kasamatsu T, Kodaira T, Yoshimura R, Ishikura S, Hiraoka M. A Consensus-based Guideline Defining Clinical Target Volume for Primary Disease in External Beam Radiotherapy for Intact Uterine Cervical Cancer. Jpn J Clin Oncol 2011; 41:1119-26. [DOI: 10.1093/jjco/hyr096] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Saitoh T, Kasamatsu T, Inoue M, Mitsui T, Koiso H, Yokohama A, Handa H, Matsushima T, Tsukamoto N, Karasawa M, Ogawara H, Nojima Y, Murakami H. Interleukin-10 gene polymorphism reflects the severity of chronic immune thrombocytopenia in Japanese patients. Int J Lab Hematol 2011; 33:526-32. [PMID: 21463487 DOI: 10.1111/j.1751-553x.2011.01320.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
INTRODUCTION T-helper cell type 1 (Th1) polarization of the immune response has been documented in patients with chronic immune thrombocytopenia (ITP). Interleukin (IL)-10 is the most important factor regulating Th1 and T-helper type 2 cytokine synthesis. This study evaluated the impact of IL-10 polymorphisms on both susceptibility to, and severity of, chronic ITP. METHODS We analyzed -1082(G/A), -812(C/T), and -592(C/A) IL-10 polymorphisms in 90 patients with adult chronic ITP and 202 race- and sex-matched healthy controls. RESULTS No significant differences in the genotype or haplotype frequencies were observed between the patient with chronic ITP and the control group. However, more patients with the -592AA genotype showed a severe thrombocytopenic state (platelet count <10 x 10⁹/l) than those with the -592CC/CA genotypes (44.1%vs. 19.6%, P = 0.01). Furthermore, more patients with the ATA/ATA haplotype showed a severe thrombocytopenic state than those without the ATA/ATA haplotype (44.1%vs. 19.6%, P = 0.01). CONCLUSION According to our data, patients with low producer type of IL-10 polymorphisms have more severe thrombocytopenia, suggesting that IL-10 gene polymorphisms may reflect the severity of ITP.
Collapse
Affiliation(s)
- T Saitoh
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Uehara T, Onda T, Togami S, Amano T, Tanikawa M, Sawada M, Ikeda S, Kato T, Kasamatsu T. Safety and efficacy of a splenectomy during debulking surgery for Müllerian carcinoma. EUR J GYNAECOL ONCOL 2011; 32:269-273. [PMID: 21797114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
PURPOSE This study was designed to assess the safety and efficacy of a splenectomy and to analyze the prognostic factors of Müllerian carcinoma with spleen metastasis. METHODS We reviewed the medical records of 11 patients with Müllerian carcinoma who underwent a splenectomy between 1997 and 2007. The treatment outcome of these patients was examined and the possible prognostic factors were investigated by univariate analysis. RESULTS Four and seven patients underwent a splenectomy for primary and recurrent disease, respectively. A complete resection was achieved in eight patients. A blood transfusion was not required and only two mild postoperative complications were observed. The median and five-year survivals of all patients following treatment were 39 months and 39%, respectively. Older patients (> or = 60 years old) and patients with a poor performance status (PS2) had a poorer prognosis by univariate analysis. CONCLUSIONS A splenectomy can be performed safely and effectively during debulking surgery for appropriately selected patients with primary or recurrent Müllerian carcinoma.
Collapse
Affiliation(s)
- T Uehara
- Gynecologic Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Mizunoe T, Hiura M, Kasamatsu T, Shibata T, Kamura T. Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer: Update of Japan Clinical Oncology Group (JCOG) Protocol 0102. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5047] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Kasamatsu T, Imamura K. Ocular dominance plasticity maintained by cyclic amp-dependent protein kinase activation: A general mechanism in visual cortex. J Vis 2010. [DOI: 10.1167/6.6.402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
36
|
Zhu Z, Lin K, Kasamatsu T. Asymmetrical response modulation between cell pair in cat striate cortex. J Vis 2010. [DOI: 10.1167/2.7.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
37
|
Borba VZC, Vieira JGH, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int 2009; 20:427-33. [PMID: 18600287 DOI: 10.1007/s00198-008-0676-1] [Citation(s) in RCA: 115] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2008] [Accepted: 05/29/2008] [Indexed: 10/21/2022]
Abstract
UNLABELLED We investigated the effects of disease activity on bone metabolism in 36 patients with systemic lupus erythematosus (SLE). Changes in bone remodeling were not explained by corticosteroid use. A high prevalence of 25OHD deficiency in SLE patients indicates the need for vitamin D replacement, mainly during high disease activity periods. INTRODUCTION We investigated the effects of SLE disease activity on bone metabolism, their relation to inflammatory cytokines and vitamin D levels. METHODS We performed a cross-sectional analysis of 36 SLE patients classified according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in high activity (group I: 12 patients, mean age 29.6 years) or in minimal activity (group II: 24 patients, mean age 30.0 years), and compared them to normal controls (group III: 26 women, 32.8 years). Serum calcium, phosphorus, parathyroid and sex hormones, bone remodeling markers, interleukin (IL)-6, soluble IL-6 receptor (sIL-6R), IL-1, tumor necrosis factor-alpha (TNF), 25-hydroxivitamin D (25OHD), and 1,25-dihydroxyvitamin D3 were measured, plus bone mineral density. RESULTS All cytokines were significantly higher in SLE groups; IL-6 could differentiate SLE patients from controls. In group I, 25OHD levels were lower (P < 0.05), which was related to the SLEDAI (R = -0.65, P < 0.001). In multiple regression analysis, the 25OHD level was associated with SLEDAI, osteocalcin and bone-specific alkaline phosphatase. The SLEDAI score was positively correlated with all measured cytokines and especially TNF (R = 0.75, P < 0.001). CONCLUSIONS SLE patients demonstrated changes in bone remodeling strongly related to disease activity. A high prevalence of 25OHD deficiency was observed in SLE patients, indicating the need for vitamin D replacement.
Collapse
Affiliation(s)
- V Z C Borba
- Division of Endocrinology, Universidade Federal de São Paulo, São Paulo, Brazil.
| | | | | | | | | | | |
Collapse
|
38
|
Sasajima Y, Mikami Y, Kaku T, Kiyokawa T, Ohishi Y, Hamada T, Sasaki T, Fujita H, Moriya T, Kasamatsu T, Tsuda H. Gross features of lobular endocervical glandular hyperplasia in comparison with minimal-deviation adenocarcinoma and stage Ib endocervical-type mucinous adenocarcinoma of the uterine cervix. Histopathology 2008; 53:487-90. [DOI: 10.1111/j.1365-2559.2008.03095.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Ogura R, Ikeda N, Yuki K, Morita O, Saigo K, Blackstock C, Nishiyama N, Kasamatsu T. Genotoxicity studies on green tea catechin. Food Chem Toxicol 2008; 46:2190-200. [DOI: 10.1016/j.fct.2008.02.016] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2007] [Revised: 02/13/2008] [Accepted: 02/18/2008] [Indexed: 01/16/2023]
|
40
|
Nishio S, Tsuda N, Kawano K, Ushijima K, Tsuda H, Kasamatsu T, Sasajima Y, Kage M, Kuwano M, Kamura T. Evaluation of Cap43/NDRG1/Drg-1 as a molecular target for angiogenesis and prognostic indicator in cervical adenocarcinoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.16525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Kasamatsu T, Sasajima Y, Onda T, Sawada M, Kato T, Tanikawa M. Surgical treatment for neuroendocrine carcinoma of the uterine cervix. Int J Gynaecol Obstet 2007; 99:225-8. [PMID: 17897648 DOI: 10.1016/j.ijgo.2007.06.051] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2007] [Revised: 06/06/2007] [Accepted: 06/07/2007] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To identify the best operative approach for neuroendocrine cervical carcinoma (NECC). METHODS The records of surgically treated patients with stages IB to IIB NECC were reviewed. RESULTS Of 10 patients who met the study criteria for NECC and underwent radical hysterectomy, 4 had pT1bN0, 4 had pT1bN1, 1 had pT2aN0, and 1 had pT2bN1 disease. Those with pT1bN1 or pT2bN1 disease received postoperative adjuvant radiotherapy and/or chemotherapy, and recurrence occurred in 7 patients (70%). Among these 7 patients, 5 (71%) had a primary NECC tumor with deep stromal invasion and 5 (71%) had extrauterine disease (parametrium and/or lymph node). The recurrences in 6 patients (86%) were located outside the pelvis (lung, liver, or brain). Stromal invasion was 6 mm or less in the 3 patients who did not experience disease recurrence. CONCLUSIONS Pelvic control by radical hysterectomy may not be beneficial for patients with NECC except for those with an early invasive lesion.
Collapse
Affiliation(s)
- T Kasamatsu
- Division of Gynecology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
| | | | | | | | | | | |
Collapse
|
42
|
Nishio S, Ushijima K, Nishida N, Yamaguchi T, Tsuda H, Kasamatsu T, Sasajima Y, Kage M, Kuwano M, Kamura T. 516 POSTER Cap43/NDRG1 is a molecular marker of angiogenesis and prognosis in cervical adenocarcinoma. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70455-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
43
|
Imamura K, Kasamatsu T, Tanaka S. Neural plasticity maintained high by activation of cyclic AMP-dependent protein kinase: an age-independent, general mechanism in cat striate cortex. Neuroscience 2007; 147:508-21. [PMID: 17544224 DOI: 10.1016/j.neuroscience.2007.04.041] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2006] [Revised: 04/24/2007] [Accepted: 04/27/2007] [Indexed: 10/23/2022]
Abstract
Adult cats lack ocular dominance plasticity, showing little change in the ocular dominance distribution following monocular deprivation. Ocular dominance plasticity is also lost in kitten visual cortex that has been continuously infused with either catecholaminergic neurotoxin, beta-adrenoreceptor blocker, or inhibitor of cyclic AMP-dependent protein kinase (protein kinase A). Complementarily, in adult cats we showed earlier that pharmacological activation of protein kinase A, albeit partially, restored ocular dominance plasticity. In the present study, we first asked whether, mediated by protein kinase A activation, the same molecular mechanisms could restore ocular dominance plasticity to kitten cortex that once lost the expression of plasticity due to prior pharmacological treatments. Concurrently with monocular deprivation, two kinds of cyclic AMP-related drugs (cholera toxin A-subunit or dibutyryl cyclic AMP) were directly infused in two types of aplastic kitten cortex pretreated with either 6-hydroxydopamine or propranolol. The combined treatment resulted in clear ocular dominance shift to the non-deprived eye, indicating that cortical plasticity was fully restored to aplastic kitten cortex. Next, to directly prove the sensitivity difference in protein kinase A activation between the immature and mature cortex, we compared the thus-obtained data in kittens with the published data derived from adult cats under the comparable experimental paradigm. The extent of ocular dominance changes following monocular deprivation was compared at different drug concentrations in the two preparations: the shifted ocular dominance distribution in aplastic kitten cortex infused with dibutyryl cyclic AMP at the lowest concentration tested and the W-shaped distribution in similarly treated adult cortex at a thousandfold-higher drug concentration that induced nearly maximal changes. We conclude that, irrespective of the animal's age, activation of protein kinase A cascades is a general mechanism to maintain ocular dominance plasticity high, their sensitivity being substantially higher in the immature than mature cortex.
Collapse
Affiliation(s)
- K Imamura
- Laboratory of Visual Neurocomputing, Brain Science Institute, RIKEN, 2-1 Hirosawa, Wako-shi, Saitama, 351-0198, Japan.
| | | | | |
Collapse
|
44
|
Abstract
Patients with stage IIB cervical cancer in some countries in Europe and Asia especially in Japan are usually treated with radical hysterectomy and pelvic lymphadenectomy. Extrauterine diseases, ie, nodal metastases, parametrial invasion, and intraperitoneal spread, can be readily identified. We present the literature review of radical hysterectomy in stage IIB cervical cancer by searching data since 1980 from Medline, and we found that the parametrial involvement of patients in this stage was only 21-55%, the incidence of pelvic node metastases was about 35-45%, and 5-year survival rate was between 55% and 77%. Lymph node metastases and the number of positive nodes were significant prognostic factors of patients in this stage.
Collapse
Affiliation(s)
- P Suprasert
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
| | | | | |
Collapse
|
45
|
Kasamatsu T, Ogura R, Ikeda N, Morita O, Saigo K, Watabe H, Saito Y, Suzuki H. Genotoxicity studies on dietary diacylglycerol (DAG) oil. Food Chem Toxicol 2005; 43:253-60. [PMID: 15621338 DOI: 10.1016/j.fct.2004.10.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2004] [Accepted: 10/05/2004] [Indexed: 11/21/2022]
Abstract
Dietary diacylglycerol (DAG) oil is an edible oil enriched in DAG (more than 80%). A recent investigation indicated that DAG oil or its components may have beneficial effects on the prevention and management of obesity. We evaluated the genotoxic potential of DAG oil using standard genotoxicity tests. Bacterial reverse mutation assay (Ames test), the chromosomal aberration assay in cultured Chinese hamster lung cells (CHL/IU), and a bone marrow micronucleus assay in ICR CD mice were employed in the present study. In addition we have tested the possibility that genotoxic substances may be formed during cooking, heated DAG oil (HDG) was prepared by batch frying potato slices in the oil at 180 degrees C for 8 h/day for three consecutive days. Therefore, genotoxicity tests were also performed on HDG. Results obtained did not show any genotoxic effect on either unheated DAG oil (UDG) or HDG. We conclude that there are no safety concerns on the genotoxicity of DAG oil under the conditions for normal use.
Collapse
Affiliation(s)
- T Kasamatsu
- Safety and Microbial Control Research Center, Kao Corporation, 2606 Akabane, Ichikai-Machi, Haga-Gun, Tochigi 321-3497, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Kasamatsu T, Onda T, Yamada T, Tsunematsu R. Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma. Int J Gynaecol Obstet 2005; 89:39-44. [PMID: 15777897 DOI: 10.1016/j.ijgo.2004.12.020] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2004] [Revised: 12/28/2004] [Accepted: 12/28/2004] [Indexed: 10/25/2022]
Abstract
OBJECTIVE To identify which patients with locally recurrent cervical carcinoma are potentially curable. METHOD A total of 664 stage IB-IVA patients were examined following surgery or radiotherapy. RESULT Among the 664 patients, 193 (29%) developed recurrence. Sixty-seven (35%) of these recurrences were located in the pelvis alone. Among these 67 recurrences, 24 (35%) were central recurrences and the remaining 43 (65%) were pelvic side-wall recurrences. Of the 24 patients with central recurrences, 8 were salvaged. Of these 8 patients, 3 underwent pelvic exenteration, and 5 received optimal radiotherapy. The recurrent tumor in these 5 survivors who received radiotherapy had consisted of a small (<2 cm) tumor. All 43 patients with pelvic wall recurrence developed progressive disease. CONCLUSION The following patients are potentially curable: patients with a resectable, centrally located tumor who are candidates for pelvic exenteration, and patients with a small central recurrence for whom complete radiation therapy is feasible.
Collapse
Affiliation(s)
- T Kasamatsu
- Division of Gynecology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
| | | | | | | |
Collapse
|
47
|
Kitagawa R, Katsumata N, Yamanaka Y, Ando M, Fujiwara Y, Kasamatsu T, Onda T, Yamada T, Tsunematsu R, Watanabe T. Phase II trial of paclitaxel (T) and carboplatin (C) in patients with recurrent or metastatic cervical carcinoma. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Kitagawa
- Shizuoka Cancer Center, Shizuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; Sanno Medical Oncology Center, Tokyo, Japan
| | - N. Katsumata
- Shizuoka Cancer Center, Shizuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; Sanno Medical Oncology Center, Tokyo, Japan
| | - Y. Yamanaka
- Shizuoka Cancer Center, Shizuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; Sanno Medical Oncology Center, Tokyo, Japan
| | - M. Ando
- Shizuoka Cancer Center, Shizuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; Sanno Medical Oncology Center, Tokyo, Japan
| | - Y. Fujiwara
- Shizuoka Cancer Center, Shizuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; Sanno Medical Oncology Center, Tokyo, Japan
| | - T. Kasamatsu
- Shizuoka Cancer Center, Shizuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; Sanno Medical Oncology Center, Tokyo, Japan
| | - T. Onda
- Shizuoka Cancer Center, Shizuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; Sanno Medical Oncology Center, Tokyo, Japan
| | - T. Yamada
- Shizuoka Cancer Center, Shizuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; Sanno Medical Oncology Center, Tokyo, Japan
| | - R. Tsunematsu
- Shizuoka Cancer Center, Shizuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; Sanno Medical Oncology Center, Tokyo, Japan
| | - T. Watanabe
- Shizuoka Cancer Center, Shizuoka, Japan; National Cancer Center Hospital, Tokyo, Japan; Sanno Medical Oncology Center, Tokyo, Japan
| |
Collapse
|
48
|
Kasamatsu T, Onda T, Katsumata N, Sawada M, Yamada T, Tsunematsu R, Ohmi K, Sasajima Y, Matsuno Y. Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus. Br J Cancer 2003; 88:245-50. [PMID: 12610496 PMCID: PMC2377042 DOI: 10.1038/sj.bjc.6600698] [Citation(s) in RCA: 100] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
A retrospective analysis was performed to evaluate the prognostic significance of peritoneal cytology in patients with endometrial carcinoma limited to the uterus. A total of 280 patients with surgically staged endometrial carcinoma that was histologically confined to the uterus were examined clinicopathologically. The median length of follow-up was 62 (range, 12-135) months. All patients underwent hysterectomy and salpingo-oophorectomy with selective lymphadenectomy, and only three patients received adjuvant postoperative therapy. No preoperative adjuvant therapy was employed. In all, 48 patients (17%) had positive peritoneal cytology. The 5-year survival rate among patients with positive or negative peritoneal cytology was 91 or 95%, respectively, showing no significant difference (log-rank, P=0.42). The disease-free survival rate at 36 months was 90% among patients with positive cytology, compared with that of 94% among patients with negative cytology, and the difference was not significant (log-rank, P=0.52). Multivariate proportional hazards model revealed only histologic grade to be an independent prognostic factor of survival (P=0.0003, 95% CI 3.02 - 40.27) among the factors analysed (age, peritoneal cytology, and depth of myometrial invasion). Multivariate analysis revealed that histologic grade (P=0.02, 95% CI 1.21-9.92) was also the only independent prognostic factor of disease-free survival. We concluded that the presence of positive peritoneal cytology is not an independent prognostic factor in patients with endometrial carcinoma confined to the uterus, and adjuvant therapy does not appear to be beneficial in these patients.
Collapse
Affiliation(s)
- T Kasamatsu
- Division of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Yoshimura N, Kinoshita H, Danjoh S, Takijiri T, Morioka S, Kasamatsu T, Sakata K, Hashimoto T. Bone loss at the lumbar spine and the proximal femur in a rural Japanese community, 1990-2000: the Miyama study. Osteoporos Int 2002; 13:803-8. [PMID: 12378369 DOI: 10.1007/s001980200111] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Bone mineral density (BMD) was measured over a ten year period in a cohort study in Miyama village, Wakayama Prefecture, Japan, to provide information on rate of bone loss in the mature and elderly population. Four hundred subjects were selected by sex and age decade from the full list of residents born in 1910-1949, and aged 40-79 years at the end of 1989, with 50 men and 50 women in each age decade. Baseline BMD of the lumbar spine and the proximal femur was measured using dual energy X-ray absorptiometry (DXA) in 1990 and again in 1993, 1997 and 2000. Annual rate of change in BMD (% per year) in the lumbar spine in men in their forties, fifties, sixties and seventies was 0.17, 0.55, 0.01 and -0.16, respectively, and in women, -0.87, -0.83, -0.48 and -0.48, respectively. Thus in men, BMD at the lumbar spine increased in all age strata but the oldest, when it decreased, whereas in women, it decreased in all age strata. On the other hand, BMD at the proximal femur decreased in both sexes in all age strata. Our results show that bone loss rates differ depending on the site involved, demonstrating that different strategies are needed for the prevention of bone loss in the spine and hip.Furthermore, we found evidence of differences in BMD for given age strata between birth cohorts. Data in 1990 and in 2000 showed significant improvements for men in their sixties and for women in their fifties, suggesting that future problems of osteoporosis might be less severe than has previously been predicted in Japan.
Collapse
Affiliation(s)
- N Yoshimura
- Department of Public Health, Wakayama Medical University School of Medicine, Wakayama, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Affiliation(s)
- Y J Kawamura
- Dept. of Surgery, Jichi Medical School, Omiya Medical Center, Saitama, Japan.
| | | | | | | | | |
Collapse
|